WO2003094972A3 - Fap-activated anti-tumor prodrugs - Google Patents

Fap-activated anti-tumor prodrugs Download PDF

Info

Publication number
WO2003094972A3
WO2003094972A3 PCT/EP2003/004713 EP0304713W WO03094972A3 WO 2003094972 A3 WO2003094972 A3 WO 2003094972A3 EP 0304713 W EP0304713 W EP 0304713W WO 03094972 A3 WO03094972 A3 WO 03094972A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrugs
fap
fapalpha
cytotoxic
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/004713
Other languages
French (fr)
Other versions
WO2003094972A2 (en
Inventor
Erik Patzelt
John Edward Park
Stefan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to AU2003233238A priority Critical patent/AU2003233238A1/en
Priority to EP03727438A priority patent/EP1506221A2/en
Publication of WO2003094972A2 publication Critical patent/WO2003094972A2/en
Publication of WO2003094972A3 publication Critical patent/WO2003094972A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to prodrugs which are capable of being converted into prodrug intermediates of a cytotoxic or cytostatic drug, by the catalytic action of FAPalpha, said prodrugs exhibit- an oligomeric part comprising up to (9) amino carboxylic acid residues, the amide bond between the C-terminal amino carboxylic acid and the preceding amino acid thereof is recognized and cleaved by FAPalpha in the immediate environment of a target cell, and- a cytotoxic or cytostatic part, wherein the N-terminal amino function of the oligomeric part is attached to a capping group (Cg).
PCT/EP2003/004713 2002-05-10 2003-05-06 Fap-activated anti-tumor prodrugs Ceased WO2003094972A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003233238A AU2003233238A1 (en) 2002-05-10 2003-05-06 Fap-activated anti-tumor prodrugs
EP03727438A EP1506221A2 (en) 2002-05-10 2003-05-06 Fap-activated anti-tumor prodrugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02010552 2002-05-10
EP02010552.4 2002-05-10

Publications (2)

Publication Number Publication Date
WO2003094972A2 WO2003094972A2 (en) 2003-11-20
WO2003094972A3 true WO2003094972A3 (en) 2004-03-18

Family

ID=29414680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004713 Ceased WO2003094972A2 (en) 2002-05-10 2003-05-06 Fap-activated anti-tumor prodrugs

Country Status (3)

Country Link
EP (1) EP1506221A2 (en)
AU (1) AU2003233238A1 (en)
WO (1) WO2003094972A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047170A1 (en) * 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
CN106573073B (en) 2014-06-13 2021-09-28 塔夫茨大学信托人 FAP-activated therapeutics and uses related thereto
WO2022136586A1 (en) 2020-12-22 2022-06-30 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014416A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
WO2000071571A2 (en) * 1999-05-14 2000-11-30 Boehringer Ingelheim Pharma Kg Fap-activated anti-tumor compounds
WO2002100353A2 (en) * 2001-06-11 2002-12-19 Medarex, Inc. Cd10-activated prodrug compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014416A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
WO2000071571A2 (en) * 1999-05-14 2000-11-30 Boehringer Ingelheim Pharma Kg Fap-activated anti-tumor compounds
WO2002100353A2 (en) * 2001-06-11 2002-12-19 Medarex, Inc. Cd10-activated prodrug compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BREISTOL K ET AL: "The antitumour activity of the prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 34, no. 10, September 1998 (1998-09-01), pages 1602 - 1606, XP004285055, ISSN: 0959-8049 *

Also Published As

Publication number Publication date
AU2003233238A1 (en) 2003-11-11
WO2003094972A2 (en) 2003-11-20
AU2003233238A8 (en) 2003-11-11
EP1506221A2 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
IL186265A0 (en) Il-21 variants
CA2651990C (en) Improved antimicrobial peptides
EP1908773B8 (en) Process for producing dipeptides
WO2007107587A3 (en) Cholesterol lowering protein hydrolysates
NZ600690A (en) Fkbp-l and uses thereof
WO2007081516A3 (en) Tumor activated prodrugs
EP1476541A4 (en) Novel cytokine zcytor17 ligand
WO2002038742A3 (en) Dipeptidylpeptidases and methods of use
EP1651166B8 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2007108013A3 (en) Novel bioconjugates as therapeutic agent and synthesis thereof
EP2455459A3 (en) Lipase variants for pharmaceutical use
EP2402369A3 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
DE60217377D1 (en) Durch thrombin spaltbare chimäre proteine
WO2007004876A3 (en) Peptides inhibiting angiotensin-converting enzyme
AU2001272504A1 (en) 4-alkoxy cyclohexane-1 amino carboxylic acid esters and method for the production thereof
WO2003094972A3 (en) Fap-activated anti-tumor prodrugs
PL2076532T3 (en) Cytokine derivatives
AU2003299038A1 (en) Synthesis and characterization of novel systems for guidance and vectorization of compounds having a therapeutic activity
AU2003248116A1 (en) Process for producing tripeptide or higher peptide
AU2865801A (en) Therapeutic peptides
WO2004074312A3 (en) Tryptophyllin peptides and uses thereof
NZ533738A (en) Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis
SI1704234T1 (en) Production of glucagon like peptide 2 and analogs
SI1539815T1 (en) Crystal structure of an angiotensin-converting enzyme (ace) and uses thereof
WO2002062831A1 (en) Novel peptides, derivatives thereof, process for producing the same, novel strains producing the same and antiviral agents containing the same as the active ingedient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003727438

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003727438

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003727438

Country of ref document: EP